

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **August 14, 2013**

AngioDynamics, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

000-50761

(Commission File Number)

11-3146460

(IRS Employer Identification No.)

14 Plaza Drive Latham, New York
(Address of Principal Executive Offices)

12110
(Zip Code)

Registrant's telephone number, including area code: **(518) 795-1400**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 7.01 – Regulation FD Disclosure.

On August 14, 2013, Mark Frost, Executive Vice President and Chief Financial Officer of AngioDynamics, Inc. (the “Company”), will present to certain investors at the 33rd Annual Canaccord Growth Conference. The conference slides are furnished herewith as Exhibit 99.1.

The slides are being furnished pursuant to Item 7.01 and the information contained therein shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities under that Section. Furthermore, the information in Exhibit 99.1 shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended.

Item 9.01 – Financial Statements and Exhibits.

(d) Exhibits.

99.1 Presentation slides for the Canaccord Growth Conference on August 14, 2013.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ANGIODYNAMICS, INC.

Date: August 14, 2013

/s/ Stephen A. Trowbridge

Stephen A. Trowbridge

Senior Vice President and General Counsel

EXHIBIT INDEX

Exhibit No.	Description	Paper (P) or Electronic (E)
99.1	Presentation slides for the Canaccord Growth Conference on August 14, 2013.	E



angiodynamics

Mark Frost, Executive Vice President and CFO
August 2013

FORWARD-LOOKING STATEMENTS

Notice Regarding Forward Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms" "intends," "anticipates," "plans," "believes," "seeks," "estimates," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics' expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate purchased businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2013. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

In the United States, NanoKnife has been cleared by the FDA for use in the surgical ablation of soft tissue. NanoKnife has not been cleared for the treatment or therapy of a specific disease or condition. This document may discuss the use of NanoKnife for specific clinical indications for which it is not cleared in the United States at this time.

Notice Regarding Non-GAAP Financial Measures

Management uses non-GAAP measures to establish operational goals, and believes that non-GAAP measures may assist investors in analyzing the underlying trends in AngioDynamics' business overtime. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this presentation, AngioDynamics has reported non-GAAP sales growth, non-GAAP gross margin, non-GAAP operating income, adjusted EBITDA (income before interest, taxes, depreciation and amortization), non-GAAP net income and non-GAAP earnings per share. Management uses these measures in its internal analysis and review of operational performance. Management believes that these measures provide investors with useful information in comparing AngioDynamics' performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance of AngioDynamics' underlying business. Management encourages investors to review AngioDynamics' financial results prepared in accordance with GAAP to understand AngioDynamics' performance taking into account all relevant factors, including those that may only occur from time to time but have a material impact on AngioDynamics' financial results. Please see the tables that follow for a reconciliation of non-GAAP measures to measures prepared in accordance with GAAP.

ANGIODYNAMICS AT A GLANCE

Corporate History

Founded 1988 | IPO May 2004 | ANGO (NASDAQ)
Acquired Microsulis (2013) | Vortex Medical (2012)
Navilyst (2012) | Oncobionic (2008) | RITA Medical (2007)

Worldwide Presence

Albany NY - HQ | 1,400 Employees | 7 Operating Locations

Global Selling Reach

120+ person direct sales team in U.S.
50+ markets through 110+ distributors
20+ sales reps in Australia, Canada, France, Germany, Netherlands and UK



A NEW DAY FOR ANGIODYNAMICS

Strategic Imperatives

- Develop innovative, differentiated and high quality products for clinicians and patients
- Focus our investments in product categories and geographic markets that offer sustainable, profitable growth
- Enhance our profitability by driving operation excellence across the entire organization

Long-term
Objectives

Grow
revenues
8-10%

Recognized globally as
a leading provider
of innovative,
image guided, minimally
invasive solutions.

Grow
earnings
at a mid
teens rate

Three Global Businesses Focused on Innovation

Peripheral
Vascular
PV

- Automated fluid management
- Thrombolysis/thrombectomy/PE
- Comprehensive venous strategy

Vascular
Access
VA


- BioFlo as a platform technology
- Advanced techniques & procedures
- New technologies

Oncology/
Surgery
O/S

- NanoKnife standard-of-care
- Thermal ablation
- Interventional oncology


Transformation to a Double-Digit Growth Company

FY 2013: Flat Sales; 50% GM%



Transformation to a Double-Digit Growth Company

Long-Term: ~10% Sales Growth; 60% GM%



PERIPHERAL VASCULAR BUSINESS

PV
Peripheral
Vascular



Fluid Management
Thrombus Management
Varicose Vein Ablation
Angiographic/Drainage Catheters



Strategic Objectives

Reinvigorate
NAMIC

Build Thrombus
Management

Expand EVLT
Adoption

Grow
Core

Key Growth Drivers

- **AngioVac Adoption**
- **Channel Synergy**
 - Fluid Management in IR/Vascular
 - Venous Ablation in Cardiology
 - Core Products in Cardiology
- **Automated Power Injector (API)**

Global Net Sales


<i>\$ in millions</i>	FY13
Fluid Mgmt	\$81
VenaCure EVLT	\$46
AngioVac	\$2
Core Products	\$51
Total PV	\$180

The Opportunity

Venous Thromboembolism (VTE) Incidence

•Overall ~1 Million VTE Events per Year in US

•Overall 300,000 VTE Deaths per Year in US - #3 cause



Additional:
Annual Incidence

Catheter/Lead RA
200,000

RA Mass
47,000

IVCF Thrombosis
14,000

TV Endocarditis
2,500

8 Heit JA, et al. *Blood*. 2005; 106:267A.
Murphy SL, et al. Deaths: Preliminary Data for 2010. National Vital Statistics Reports; 2012




Current market concerns that the NAMIC API will address:

- Extended learning curve
- Long set up time
- Lack of flow restriction indicator
- Uncontrolled contrast dosage to the patient
- Contrast use and waste per procedure
- Unreliable hemodynamics readings

Additional solutions provided by NAMIC API

- Greater control
- Reduced per procedure costs
- Provide greater protection and safety




VENACURE EVLT

The Power of Water...

PV

Large Underpenetrated Market Opportunity



- \$240 million Global market, with 3-5% CAGR
- 140,000+ VenaCure EVLT procedures in FY2013
- ANGO has ~27% share of Venous Ablation market and ~54% share of the Laser Ablation market
- Installed base of ~ 4,000 units WW, including ~ 500 new 1470 lasers since launch in June 2011

NeverTouch Direct[™] Procedure Kit



Advantages of NeverTouch Direct

- Less focal charring of vein wall
- Reduced perforations
- Enhanced trackability
- Faster procedure time

VASCULAR ACCESS BUSINESS



- PICC Lines
- Implantable Ports
- Dialysis & Renal Infusion



Strategic Objectives

- Penetrate & Convert
- BIOFLO BIOFLO
BIOFLO
- Grow Int'l from 10% to 25% of revenue

Key Growth Drivers

- BioFlo PICCs
- BioFlo Ports & BioFlo Dialysis Catheters
510(k)s planned for FY14
- Tip Location
Distribution agreement
- Penetration of IDNs/GPOs

Global Net Sales

<i>\$ in millions</i>	FY13
PICCs	\$52
Ports	\$31
Dialysis/Other	\$24
Total VA	\$107

2.7M PICCs placed by nurses & Physicians in 2012¹



Symptomatic 3-7.8%

PICC-Related UEDVT Incidence Rates^{2,3}

UEDVT Incidents

81,000-211,000



Estimated Cost Per Incident⁴

\$11,957



U.S. Cost
of Hospital-Acquired DVT

\$1B - \$2.5B

¹ US MARKETS FOR VASCULAR ACCESS DEVICES 2012 - Millennium Research Group

² Evans SR, Sharp JH, Lorraine LH, et al. CHEST 2010; 138; 803-810

³ Cowl CT, et al. Complications and cost associated with parenteral nutrition delivered to hospitalized patients through either subclavian or peripherally inserted central catheters Clinical Nutrition (2000) 19 (4): 237-243


⁴ Lissovoy Gd, et al. Cost for Inpatient Care of Venous Thrombosis. Arch Intern Med. 2000;160:3160-3165.

BIOFLO TECHNOLOGY (cont'd)


VA

A Revolutionary PICC Technology...

Current Next Generation PICC Technologies



The BioFlo™ Advantage...



Unlike other technologies that are superficial and/or transient, BioFlo is designed to be both **integral to the catheter** and **permanent**

NO HEPARIN

Minimizes complications associated w/ heparin

NO ANTIBIOTICS

Reduces risks associated w/ bacterial resistance

NOT A COATING

Present throughout entire catheter

NOT ELUTING

Present for life of device

NOTE: BioFlo has been cleared in the U.S., approved in Canada, and CE Marked in Europe

BIOFLO TECHNOLOGY (cont'd)

Prospective Customer Evaluation of BioFlo

VA

Hospital	BioFlo PICC Placements (6 months)	DVTs	DVT RATE
Hillcrest ¹	276	0	0
Cleveland Clinic ²	373	1	0.2%

¹ Presented at Ohio Association for Healthcare Quality conference on May 17, 2013.

² Presented at INS May 21, 2013.

Preliminary Retrospective Analysis

BARD PowerPICC Solo2[®]
vs.
BioFlo with PASV PICC



Impact of BioFlo

- **48% reduction in occlusions**
- **38% reduction in t-PA use**
- **37% reduction in DVT**

Metric	PowerPICC Solo 2	BioFlo w/ PASV
PICCs Placed	60	133
OcclusionRate	9.63/1,000 catheter days	4.96/1,000 catheter days
T-PA Usage Rate	12.84 doses/1,000 catheter days	7.93 doses/1,000 catheter days
DVT Rate	0.80/1,000 catheter days	0.50/1,000 catheter days

NOTE: Preliminary retrospective data analysis conducted outside the U.S. by independent investigator. BioFlo has been cleared in the U.S., approved in Canada, and CE Marked in Europe.

ONCOLOGY / SURGERY BUSINESS



- Radiofrequency Ablation
- Microwave Ablation
- Irreversible Electroporation
- Resection & Embolization



Strategic Objectives

Drive NanoKnife Adoption

Increase Thermal Ablation Share

Invest in Clinical Development

Key Growth Drivers

- NanoKnife Data
- Microwave



Global Net Sales

<i>\$ in millions</i>	FY13
Thermal Ablation	\$28
NanoKnife	\$13
Other Products	\$6
Total O/S	\$47

Microsulis

We believe Microsulis is the leading microwave tumor ablation technology on the market today

“Everything we wanted in a microwave device...”

-Current AngioDynamics RFA Customer

- 2.45Ghz system for faster tissue penetration
- Single applicator
- 5 cm ablation
- Fast ablation times
- Predictable volumes of coagulation
- Attractive pricing and gross margins



 **angiodynamics**

EXPANDING OUR LEADERSHIP IN TUMOR ABLATION

AngioDynamics offers a full complement of tumor ablation products that provide clinicians maximum choice in treating patients



"The US Nonvascular Interventional Radiology market with the fastest growth and greatest potential is the ablation device market"

- MRG Nov. 2012

NAVILYST INTEGRATION



- **\$10M in FY13 savings achieved & at least \$15 million in FY14 planned**
- **Organizational changes completed**
- **Management team now in place - best talent from both organizations**
 - New CFO
 - New Head of Quality
 - New Head of Queensbury Manuf.
 - New Chief Tech/Ops Officer
 - New Head of Regulatory
 - New Medical Director
- **Creation of three global businesses to achieve greater focus on customers and markets**

Announcement
Jan 31, 2012

FY13

FY14



- ✓ Synergies ahead of \$5-7M plan
- ✓ R&D organization changes implemented
- ✓ Quality organization/process revamped
- ✓ Sales/Mktg organization course correction completed
- ✓ Robust product pipeline established

- ERP Implementation
- Functional shared service consolidation
- Accelerating ops excellence activities
 - Lean
 - Supply Chain

FISCAL 2013 FY RESULTS

\$ in millions, except
per share amounts

	FY 2013 (a)(b)	Reported YOY Growth
WW Sales	\$342.0	54%
<i>% growth</i>	<i>(1%)</i>	
Vascular Sales	\$286.4	80%
<i>% growth</i>	<i>(2%)</i>	
Onc/Surg Sales	\$47.2	(25%)
<i>% growth</i>	<i>14%</i>	
U.S. Sales	\$274.8	46%
<i>% growth</i>	<i>(4%)</i>	
Int'l Sales	\$67.2	100%
<i>% growth</i>	<i>15% constant currency</i>	
Adjusted EBITDA	\$52.2	95%
Adjusted EPS	\$0.35	67%
Adjusted EPS (excl. amort.)	\$0.64	42%

(a) As if AngioDynamics (excluding LC Beads) and Navilyst Medical were combined in all periods.

(b) Days sales outstanding for the twelve months ended May 31, 2013 and May 31, 2012, were 251 and 252 days, respectively.

FISCAL 2014 GUIDANCE

*\$ in millions, except
per share amounts*

	Adjusted Non-GAAP Q1	Adjusted Non-GAAP Full Year
Sales	\$81 — \$84	\$346 — \$352
EBITDA (a) (b)	N/A	\$52 — \$54
EPS (c)	\$0.02 — \$0.04	\$0.31 — \$0.35
EPS (c) (d)	\$0.10 — \$0.12	\$0.61 — \$0.65


(a) Adjusted result reflects an estimated \$7 million in acquisition-related and restructuring costs and \$3 million of purchase accounting expenses.

(b) \$17 million in amortization, \$9 million in depreciation, and \$3 million in purchase accounting expenses related to Vortex Medical and Microsulis acquisitions are excluded.

(c) Approximately 36 million diluted shares outstanding and a 37% tax rate.

(d) Excluding amortization for intangible assets.

INVESTMENT SUMMARY





angiodynamics

AngioDynamics, the AngioDynamics logo and other trademarks displayed in this presentation are trademarks owned and used by AngioDynamics, Inc. © Copyright 2012 AngioDynamics, Inc. All rights reserved.

INCOME STATEMENT^{(a)(b)}

*\$ in millions, except
per share amounts*

	FY 2013 ^(a)	FY 2012 ^{(b)(c)}	% Change
Sales	\$342.0	\$344.6	(1%)
Gross Margin	51.2%	51.9%	
Operating Expenses	\$148.1	\$155.5	(5%)
Operating (loss) Income	\$27.0	\$23.3	16%
Operating Margin	7.9%	6.7%	
Net Income	\$12.2	\$9.2	32%
Adjusted EPS	\$0.35	\$0.26	35%
Adjusted EPS (ex. amort)	\$0.64	\$0.54	19%
Adjusted EBITDA	\$52.2	\$47.9	9%

(a) FY13 excludes acquisition & restructurings, QCTA, Inventory step-up, and contingent earn out revaluation.

(b) FY12 is proforma and excludes LC Beads business

(c) FY12 reported adjusted EPS is \$0.21 and adjusted EPS (excl. amort.) was \$0.45.

24



BALANCE SHEET AND CASH FLOW

<i>\$ in millions</i>	FY 2013	FY 2012
Cash and investments	\$24.0	\$40.1
Net working capital	\$77.8	\$103.8
Total assets	\$791.9	\$721.8
Total debt	\$142.5	\$150.0
Total stockholders' equity	\$526.8	\$523.5

*\$ in millions, except
per share amounts*

Cash flow from operations	\$26.3	\$11.5
CFFO/share	\$0.74	\$0.45
Free cash flow	\$14.8	\$9.0